Verona Pharma Plc ADR [NASDAQ: VRNA] jumped around 17.91 points on Wednesday, while shares priced at $104.77 at the close of the session, up 20.62%.
Verona Pharma Plc ADR stock is now 550.34% up from its year-to-date (YTD) trading value. VRNA Stock saw the intraday high of $104.92 and lowest of $104.73 per share. The company’s 52-week high price is 99.01, which means current price is +141.18% above from all time high which was touched on 07/09/25.
Compared to the average trading volume of 1.32M shares, VRNA reached a trading volume of 65643137 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Verona Pharma Plc ADR [VRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRNA shares is $112.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRNA stock is a recommendation set at 2.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Verona Pharma Plc ADR shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 01, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on April 28, 2025, representing the official price target for Verona Pharma Plc ADR stock. Previously, the target price had yet another raise to $80, while Cantor Fitzgerald analysts kept a Overweight rating on VRNA stock.
The Price to Book ratio for the last quarter was 39.36, with the Price to Cash per share for the same quarter was set at 4.72.
How has VRNA stock performed recently?
Verona Pharma Plc ADR [VRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.79. With this latest performance, VRNA shares gained by 24.22% in over the last four-week period, additionally plugging by 124.88% over the last 6 months – not to mention a rise of 125.60% in the past year of trading.
Verona Pharma Plc ADR [VRNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Verona Pharma Plc ADR [VRNA] shares currently have an operating margin of -116.50% and a Gross Margin at 94.03%. Verona Pharma Plc ADR’s Net Margin is presently recorded at -138.52%.
Return on Equity for this stock declined to -40.26%, with Return on Assets sitting at -40.26%.
Insider trade positions for Verona Pharma Plc ADR [VRNA]
There are presently around $90.98%, or 101.54% of VRNA stock, in the hands of institutional investors. The top three institutional holders of VRNA stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.63 million shares, which is approximately 1.1775%. MORGAN STANLEY, holding 0.86 million shares of the stock with an approximate value of $$12.49 million in VRNA stocks shares; and MORGAN STANLEY, currently with $$80.76 million in VRNA stock with ownership which is approximately 0.8616%.
